Emactuzumab

• Description:

  Emactuzumab (RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) [1][2].

• Product Name Alternative:

  RG 7155; RO 5509554

• UNSPSC:

  12352203

• Target:

  C-Fms

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/emactuzumab.html

• Purity:

  97.60

• Solubility:

  10 mM in DMSO

• Smiles:

  [Emactuzumab]

• Molecular Weight:

  (144.41 kDa)

• References & Citations:

  [1]Philippe A Cassier, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015 Aug;16 (8) :949-56.|[2]Carola H Ries, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25 (6) :846-59.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 3

• CAS Number:

  1448221-67-7